Printer Friendly

Research and Markets: Global Hemophilia Market Report: 2012 Edition.

DUBLIN -- Research and Markets ( has announced the addition of the "Global Hemophilia Market Report: 2012 Edition" report to their offering.

The market for hemophilia products has shown continuous growth in the past years growing at a CAGR of around 8.96% during 2006-11 and is projected to expand steadily in the years to come.

The occurrence rate of bleeding disorders such as hemophilia is increasing, calling for an increased usage of blood plasma products. The male population of the world is rising and males are the ones who are worst affected by hemophilia as they carry only one X chromosome. Females are only the carriers of this disease. Furthermore, the increasing expenditure is also responsible for higher utilization of recombinant and plasma derived coagulation factors. The existing treatments for hemophilia treatment comprise of blood plasma derivatives and recombinant factors.

The key trends in the hemophilia treatment market are the increasing inclination towards prophylaxis, limiting the use of central venous access device for prophylactic treatment, development of long-acting Factor VIII and IX, deep penetration of rFVIII products within the emerging markets. The recent developments in the respective field include gene therapy for treating hemophilia B, half life extension of the recombinant coagulation factors, development of 4-factor PCC for reversal of vitamin K antagonist anticoagulant therapy along with recent approval of ADVATE in China apart from other clinical trials on run.

The major factors driving the growth of the industry are the increasing number of new patients registering themselves for treatment at the hospitals and other healthcare institutions, growing male population, rising expenditure on healthcare globally, and the increased life expectancy for hemophilia patients.


The report provides an analysis of the global hemophilia treatment market. It also discusses the major trends, growth drivers and potential markets. The report presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.

Key Topics Covered

1. Hemophilia: An Overview

2. Market Overview

- Global Heamophilia Market

- Global Hemophilia Market by Type

- Global Hemophilia Therapeutics Market by Region

3. Hemophilia Market Dynamics

- Key Trends

- Industry Developments

- Growth Drivers

- Challenges

4. Hemophilia Market - Competitive Scenario

5. Company Profiles

6. Market Outlook

Companies Mentioned

- Baxter International

- Grifols

- Novo Nordisk

- Pfizer, Inc.

For more information, including full table of contents, please visit
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Industry overview
Date:Jul 10, 2012
Previous Article:Research and Markets: Qatar Projects Market Organogram 2012. The Who's Who In The Qatar Projects Market.
Next Article:Europe Peripheral Vascular Device Market Report by iData Research Now Available at

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters